首页> 美国卫生研究院文献>Journal of Diabetes Science and Technology >Advances in Insulin Pen Technologies: Development and Testing of Solid Dose Formulations Containing Polysialic Acid Insulin Conjugate: Next Generation of Long-Acting Insulin
【2h】

Advances in Insulin Pen Technologies: Development and Testing of Solid Dose Formulations Containing Polysialic Acid Insulin Conjugate: Next Generation of Long-Acting Insulin

机译:胰岛素笔技术的进步:包含多唾液酸胰岛素结合物的固体剂型的开发和测试:下一代长效胰岛素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe need for lifelong, daily insulin injections can have a dramatic effect on patient compliance, can be painful, and runs the risk of local infections. Furthermore, needle-stick injuries are common, and the issue of needle disposal is troublesome. Injecting a long-acting insulin analog with needle-free administration would be a significant improvement for diabetic subjects, but is not currently feasible. To achieve a constant, reliable delivery of a novel, long-acting insulin analog, Lipoxen's SuliXen® (polysialylated insulin) in a solid dosage form capable of being delivered without a needle has been developed. The aim of this study was to evaluate the feasibility of Lipoxen's SuliXen delivery with the Glide solid dose injector, Glide SDI®.
机译:背景技术终身每天注射胰岛素的需求可能会对患者的依从性产生巨大影响,可能会很痛苦,并存在局部感染的风险。此外,针刺受伤是普遍的,并且针头处置问题很麻烦。无针给药注射长效胰岛素类似物对于糖尿病患者将是显着的改善,但目前尚不可行。为了稳定,可靠地输送新型长效胰岛素类似物,已开发出可以不用针头进行输送的固体剂型Lipoxen's SuliXen ®(聚唾液酸化胰岛素)。这项研究的目的是评估使用Glide固体剂量注射器Glide SDI ®进行Lipoxen SuliXen递送的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号